16,441 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Bought by WINTON GROUP Ltd

WINTON GROUP Ltd bought a new position in Hims & Hers Health, Inc. (NYSE:HIMS) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 16,441 shares of the company’s stock, valued at approximately $332,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Victory Capital Management Inc. grew its position in Hims & Hers Health by 23.0% in the fourth quarter. Victory Capital Management Inc. now owns 18,348 shares of the company’s stock worth $163,000 after acquiring an additional 3,429 shares in the last quarter. Diversify Advisory Services LLC purchased a new position in Hims & Hers Health in the first quarter worth $701,000. Sei Investments Co. grew its position in Hims & Hers Health by 206.9% in the first quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock worth $869,000 after acquiring an additional 37,890 shares in the last quarter. Quantbot Technologies LP grew its position in Hims & Hers Health by 3,444.9% in the first quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock worth $3,321,000 after acquiring an additional 208,621 shares in the last quarter. Finally, Quadrature Capital Ltd boosted its position in Hims & Hers Health by 494.2% during the first quarter. Quadrature Capital Ltd now owns 201,043 shares of the company’s stock valued at $3,108,000 after buying an additional 167,211 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at $487,789.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Hims & Hers Health news, COO Melissa Baird sold 17,625 shares of the firm’s stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $20.51, for a total transaction of $361,488.75. Following the completion of the transaction, the chief operating officer now owns 585,800 shares of the company’s stock, valued at $12,014,758. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the sale, the chief executive officer now owns 33,502 shares in the company, valued at approximately $487,789.12. The disclosure for this sale can be found here. Over the last quarter, insiders sold 701,904 shares of company stock valued at $12,349,805. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Price Performance

HIMS stock opened at $16.31 on Thursday. Hims & Hers Health, Inc. has a 1 year low of $5.65 and a 1 year high of $25.74. The company has a market cap of $3.50 billion, a P/E ratio of -1,631.00 and a beta of 1.05. The firm has a 50-day moving average of $17.54 and a 200 day moving average of $17.04.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The company had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. During the same period in the prior year, the firm earned ($0.03) earnings per share. Hims & Hers Health’s revenue was up 51.8% on a year-over-year basis. On average, equities research analysts expect that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HIMS has been the subject of several analyst reports. Bank of America cut their price target on shares of Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, September 13th. Truist Financial upped their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, July 18th. TD Cowen upped their price target on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. Piper Sandler restated a “neutral” rating and set a $18.00 price target on shares of Hims & Hers Health in a research report on Tuesday, August 6th. Finally, Citigroup lowered shares of Hims & Hers Health from a “buy” rating to a “neutral” rating and upped their price target for the company from $16.00 to $20.00 in a research report on Wednesday, May 22nd. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $19.86.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.